AMGN - Amgen Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
183.55
-0.05 (-0.03%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close183.60
Open183.80
Bid174.30 x 500
Ask174.42 x 200
Day's Range182.68 - 186.12
52 Week Range152.16 - 201.23
Volume4,365,816
Avg. Volume3,385,609
Market Cap132.259B
Beta1.67
PE Ratio (TTM)68.23
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield5.28 (2.88%)
Ex-Dividend Date2018-02-14
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • PR Newswire4 days ago

    Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO® (blinatumomab)

    THOUSAND OAKS, Calif., Feb. 14, 2018 /PRNewswire/ -- Amgen (AMGN) today announced that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data supporting the BLINCYTO® (blinatumomab) supplemental Biologics License Application (sBLA) for the treatment of patients with minimal residual disease (MRD)-positive B-cell precursor acute lymphoblastic leukemia (ALL) at a meeting on March 7, 2018. MRD refers to the presence of a small amount of detectible cancer cells that remain in the patient after treatment. "After achieving remission, the presence of MRD is the strongest prognostic factor for relapse in acute lymphoblastic leukemia.

  • ACCESSWIRE7 days ago

    Today’s Research Reports on Trending Tickers: Amgen and Celgene

    NEW YORK, NY / ACCESSWIRE / February 12, 2018 / U.S. markets managed to finish in the green on Friday, despite concerns of rising interest rates and inflationary pressure. The Dow Jones Industrial Average ...

  • PR Newswire10 days ago

    Results From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology

    THOUSAND OAKS, Calif., Feb. 8, 2018 /PRNewswire/ -- Amgen (AMGN) today announced results from the XGEVA® (denosumab) Phase 3 '482 study, the largest international multiple myeloma trial for the prevention of skeletal-related events ever conducted (n=1,718), were published in The Lancet Oncology. In this study, XGEVA successfully met the primary endpoint, demonstrating non-inferiority to zoledronic acid in delaying the time to first on-study skeletal-related event in patients with multiple myeloma (HR=0.98, 95 percent CI: 0.85-1.14).

  • PR Newswire10 days ago

    Amgen To Present At The 7th Annual Leerink Partners Global Healthcare Conference

    THOUSAND OAKS, Calif. , Feb. 8, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 7 th Annual Leerink Partners Global Healthcare Conference at 10 a.m. ET on Wednesday, Feb. 14, 2018 , in New ...

  • PR Newswire17 days ago

    Amgen Reports Fourth Quarter And Full Year 2017 Financial Results

    Expects to Increase Investments in Growth, Including a New U.S. Manufacturing Plant Announces 2018 Guidance Additional $10 Billion of Share Repurchases Authorized THOUSAND OAKS, Calif. , Feb. 1, 2018 /PRNewswire/ ...

  • PR Newswire20 days ago

    Amgen Receives CHMP Positive Opinion To Add Updated Overall Survival Data To KYPROLIS® (carfilzomib) Label

    Label Variation to Include Overall Survival Data From Phase 3 ENDEAVOR Trial THOUSAND OAKS, Calif. , Jan. 30, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products ...

  • PR Newswire20 days ago

    Amgen Announces Webcast of 2017 Fourth Quarter and Full Year Financial Results

    THOUSAND OAKS, Calif., Jan. 29, 2018 /PRNewswire/ -- Amgen (AMGN) today announced that it will report its fourth quarter and full year 2017 financial results on Thursday, Feb. 1, 2018, after the close of the U.S. financial markets. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors.

  • PR Newswire27 days ago

    Amgen Reports Aimovig™ (Erenumab) Met All Primary And Secondary Endpoints In Unique Phase 3b Study In Episodic Migraine Patients Who Have Failed Multiple Prior Preventive Treatments

    THOUSAND OAKS, Calif., Jan. 22, 2018 /PRNewswire/ -- Amgen (AMGN) today announced positive results from the Phase 3b LIBERTY study assessing the efficacy and safety of Aimovig™ (erenumab) 140 mg in patients with episodic migraine who had experienced two to four previous preventive treatment failures, due to lack of efficacy or intolerable side effects. The study met its primary endpoint, with significantly more patients taking Aimovig experiencing at least a 50 percent reduction from baseline in their monthly migraine days as compared to placebo. LIBERTY also met all secondary endpoints, including reduction of monthly migraine days, reduction in days needing acute (rescue) medication, improvement in scores on the Migraine Physical Function Impact Diary (MPFID) tool, and 75 percent and 100 percent responder rates (number of patients experiencing at least a 75 percent or 100 percent reduction in monthly migraine days compared to placebo).

  • PR Newswirelast month

    European Commission Approves Amgen And Allergan's MVASI® (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer

    THOUSAND OAKS, Calif., Jan. 18, 2018 /PRNewswire/ -- Amgen (AMGN) and Allergan plc. (AGN) today announced that the European Commission (EC) has granted marketing authorization for MVASI® (biosimilar bevacizumab).

  • PR Newswirelast month

    FDA Approves Addition Of Overall Survival Data To KYPROLIS® (carfilzomib) Label

    THOUSAND OAKS, Calif., Jan. 17, 2018 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to add overall survival (OS) data from the Phase 3 head-to-head ENDEAVOR trial to the Prescribing Information for KYPROLIS® (carfilzomib).

  • PR Newswirelast month

    Overall Survival Analysis From KYPROLIS® (Carfilzomib) Phase 3 ASPIRE Trial Published in the Journal of Clinical Oncology

    KYPROLIS, Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone Alone in Patients With Relapsed or Refractory Multiple Myeloma Results Support Early ...

  • GlobeNewswirelast month

    Biocartis Group NV: Biocartis and Amgen Sign New Companion Diagnostic Agreement for Novel Oncology Compound

    PRESS RELEASE : 9 January 2018, 07:01 CET   Biocartis and Amgen Sign New Companion Diagnostic Agreement for Novel Oncology Compound   Mechelen, Belgium, 9 January 2018 - Biocartis Group NV (the `Company` ...

  • PR Newswirelast month

    European Medicines Agency Accepts Filing For EVENITY™ (Romosozumab)

    THOUSAND OAKS, Calif. and BRUSSELS, Jan. 7, 2018 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for EVENITY™* (romosozumab) for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. If approved in Europe, EVENITY will be a novel osteoporosis treatment that increases bone formation and reduces bone resorption simultaneously to increase bone mineral density (BMD) and reduce the risk of fracture.

  • PR Newswirelast month

    FDA Approves XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma

    THOUSAND OAKS, Calif., Jan. 5, 2018 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for XGEVA® (denosumab) to expand the currently approved indication for the prevention of skeletal-related events in patients with bone metastases from solid tumors to include patients with multiple myeloma. The approval is based on data from the pivotal Phase 3 '482 study, the largest international multiple myeloma clinical trial ever conducted, which enrolled 1,718 patients. "Up to 40 percent of patients remain untreated for the prevention of bone complications, and the percentage is highest among patients with renal impairment at the time of diagnosis," said Noopur Raje, M.D., director, Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston.

  • PR Newswirelast month

    Amgen To Present At The 36th Annual J.P. Morgan Healthcare Conference

    THOUSAND OAKS, Calif. , Jan. 4, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the 36 th Annual J.P. Morgan Healthcare Conference at 8:30 a.m. PT on Tuesday , Jan. 9, 2018, in San Francisco ...

  • PR Newswire2 months ago

    Amgen Teams Up With Cambridge Biotech Community To Select Two Startups To Receive Golden Tickets At LabCentral

    CAMBRIDGE, Mass., Dec. 14, 2017 /PRNewswire/ -- Amgen (AMGN) and LabCentral today announced that Kernal Biologics Inc. and QurAlis have won the Amgen Golden Ticket at LabCentral. The two Golden Ticket winners were chosen by an Amgen internal committee and live audience members at a "Quick Pitch" event hosted by Amgen at its Cambridge R&D and Operations facility on Dec. 11, 2017.

  • PR Newswire2 months ago

    Amgen Announces 15 Percent Increase In 2018 First Quarter Dividend

    THOUSAND OAKS, Calif., Dec. 12, 2017 /PRNewswire/ -- Amgen (AMGN) today announced that its Board of Directors declared a $1.32 per share dividend for the first quarter of 2018. Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

  • PR Newswire2 months ago

    KYPROLIS® (carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma In Phase 3 ASPIRE Trial

    Results Highlighted During Oral Presentation at ASH 2017 Addition of KYPROLIS to Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone Alone Regulatory ...

  • PR Newswire2 months ago

    Amgen Foundation Pledges Up To $500,000 In Relief To Victims Of The Southern California Wildfires

    THOUSAND OAKS, Calif., Dec. 11, 2017 /PRNewswire/ -- Amgen (AMGN) today announced that the Amgen Foundation has pledged $500,000 to support victims of the Southern California wildfires. Of this commitment, $200,000 will be directed to the United Way of Ventura County to support their immediate relief efforts.

  • PR Newswire2 months ago

    New Data To Be Presented At ASH 2017 Underscore Amgen's Commitment To Improving Lives And Changing Outcomes For Patients With Difficult-To-Treat Blood Cancers

    THOUSAND OAKS, Calif., Dec. 7, 2017 /PRNewswire/ -- Amgen (AMGN) today announced that new clinical data and analyses from 33 abstracts, including six oral presentations, evaluating approved medicines and investigational immuno-oncology agents from the Company's robust hematology portfolio and pipeline will be presented at the 59th American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Dec. 9-12, 2017. The breadth and depth of data to be presented at ASH highlight Amgen's commitment to advancing treatment options for patients with some of the most difficult-to-treat blood cancers and disorders. Notably at ASH, positive overall survival (OS) results from the Phase 3 ASPIRE trial will be detailed for the first time in an oral presentation, which showed the addition of KYPROLIS® (carfilzomib) to lenalidomide and dexamethasone (KRd) significantly extended OS versus lenalidomide and dexamethasone (Rd) alone in patients with relapsed or refractory multiple myeloma.

  • PR Newswire2 months ago

    Amgen To Webcast Investor Call At ASH 2017

    THOUSAND OAKS, Calif., Dec. 6, 2017 /PRNewswire/ -- Amgen (AMGN) will host a webcast call for the investment community at the 59th American Society of Hematology (ASH) Annual Meeting & Exposition on Saturday, Dec. 9, 2017, at 11:30 a.m. ET. David M. Reese, M.D., senior vice president of Translational Sciences and Oncology at Amgen, together with other members of Amgen's management team and a clinical investigator, will participate to discuss the Company's oncology program, including our BiTE® immunotherapy platform. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar.

  • GlobeNewswire3 months ago

    Analysis: Positioning to Benefit within Emerson Electric, Puma Biotechnology, Amgen, SunCoke Energy Partners, Carrols Restaurant Group, and First Financial — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Dec. 04, 2017-- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of ...

  • GlobeNewswire3 months ago

    Biocartis Group NV: Biocartis and Amgen Sign Companion Diagnostic Agreement for Idylla(TM) RAS Biomarker Tests

    PRESS RELEASE :  4 December 2017, 07:00 CET   Biocartis and Amgen Sign Companion Diagnostic Agreement for Idylla(TM) RAS Biomarker Tests Agreement aims to deliver faster biomarker results to realize more ...

  • PR Newswire3 months ago

    FDA Approves Amgen's Repatha® (evolocumab) To Prevent Heart Attack And Stroke

    Following FDA Priority Review, Repatha is the Only PCSK9 Inhibitor Approved to Reduce Risk of Heart Attack, Stroke and Coronary Revascularization THOUSAND OAKS, Calif. , Dec. 1, 2017 /PRNewswire/ -- Amgen ...

  • Aimovig™ (erenumab) Phase 3 STRIVE Data Published In The New England Journal Of Medicine Demonstrate Significant, Sustained Efficacy In Migraine Prevention
    PR Newswire3 months ago

    Aimovig™ (erenumab) Phase 3 STRIVE Data Published In The New England Journal Of Medicine Demonstrate Significant, Sustained Efficacy In Migraine Prevention

    THOUSAND OAKS, Calif., Nov. 29, 2017 /PRNewswire/ -- Amgen (AMGN) today announced that the New England Journal of Medicine (NEJM) published positive results from the six-month Phase 3 STRIVE study evaluating Aimovig™ (erenumab) versus placebo for the prevention of episodic migraine (between four and 14 migraine days per month). Aimovig delivered clinically meaningful and statistically significant differences from placebo for all primary and secondary endpoints in the study. Patients taking Aimovig experienced a significant reduction in mean monthly migraine days and were significantly more likely to achieve a 50 percent or greater reduction in monthly migraine days than those taking placebo.